22.4-31.0 |
565-1460 |
34 |
10-5-5 |
Intravenous |
100 |
77 Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA. 1996;275(7):539-44.
|
28.1±1.1 |
934±288 |
23 |
10-5-5 |
Intravenous |
87.0 |
4343 De Carolis MP, Romagnoli C, Polimeni V, Piersigilli F, Zecca E, Papacci P, et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr. 2000;159(5):364-8.
|
28.1±1.7 |
1048±315 |
205 |
10-5-5 |
Intravenous |
84.0 |
3434 Van Overmeire B, Allegaert K, Casaer A, Debauche C, Decaluwé W, Jespers A. et al. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9449):1945-9.
|
25.6±1.4 |
757±127 |
160 |
10-10 |
Intravenous |
85.0 |
6464 Richards J, Johnson A, Fox G, Campbell M. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics. 2009;124(2):e287-93.
|
27.0±2.9 |
853±383 |
22 |
10-5-5 |
Intravenous |
72.7 |
4242 Zanardo V, Vedovato S, Lago P, Trevisanuto D, Favaro F, Faggian D, et al. Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. Pediatr Nephrol. 2005;20(11):1552-6.
|
26
|
857
|
22 |
10-5-5 |
Intravenous |
72.7 |
6565 Zanardo V, Vedovato S, Lago P, Piva D, Faggian D, Chiozza L. Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus. Fetal Diagn Ther. 2005;20(6):534-9.
|
26.6
|
994
|
30 |
10-5-5 |
Intravenous |
94.0 |
6666 Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenberghe MR, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed. 2007;92(4):F244-7.
|
26±1.7 |
835±215 |
35 |
10-5-5 |
Intravenous |
63.0
|
6767 Dani C, Vangi V, Bertini G, Pratesi S, Lori I, Favelli F, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clin Pharmacol Ther. 2012;91(4):590-6.
|
26.0±1.7 |
838±215 20 |
20 |
10-5-5 |
Intravenous |
77.0 |
6868 Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G. et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther. 2005;30(2):121-32.
|
27.7±3.2 |
1086±572 |
23 |
10-5-5 |
Intravenous |
52.6 |
6969 Meißner U, Chakrabarty R, Topf HG, Rascher W, Schroth M. Improved closure of patent ductus arteriosus with high doses of ibuprofen. Pediatr Cardiol. 2012;33(4):586-90.
|
28.3±1.1 |
1197±158 |
32 |
10-5-5 |
Intravenous |
62.5 |
4141 Cherif A, Jabnoun S, Khrouf N. Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants. Am J Perinatol. 2007;24(6):339-45.
|
28.7±2.1 |
na |
50 |
10-5-5 |
Intravenous |
62.0 |
1919 Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr. 2011;158(4):549-54.
|
26.3±1.3 |
872±123 |
34 |
10-5-5 |
Intravenous |
61.7 |
7070 Erdeve O, Yurttutan S, Altug N, Ozdemir R, Gokmen T, Dilmen U, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2012;97(4):F279-83.
|
27.5±1.75 |
979±266 |
22 |
10-5-5 |
Oral |
95.5 |
4646 Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics. 2003;112(5):e354-8.
|
na |
na |
13 |
10-5-5 |
Oral |
84.6 |
4747 Hariprasad P, Sundarrajan V, Srimathy G, Suthagar B, Ramadevi BS. Oral ibuprofen for closure of hemodynamically significant PDA in premature neonates. Indian Pediatr. 2002;39(1):99-100.
|
31.2±2.5 |
1521±398 |
12 |
10-5-5 |
Oral |
83.3 |
4848 Aly H, Lotfy W, Badrawi N, Ghawas M, Abdel-Meguid IE, Hammad TA. Oral Ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. Am J Perinatol. 2007;24(5):267-70.
|
29.4±1.0 |
1237±198 |
40 |
10-5-5 |
Oral |
95.0 |
4141 Cherif A, Jabnoun S, Khrouf N. Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants. Am J Perinatol. 2007;24(6):339-45.
|
27.8±2.4 |
1052±443 |
13 |
10 |
Oral |
100 |
5555 Barzilay B, Youngster I, Batash D, Keidar R, Baram S, Goldman M, et al. Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2012;97(2):F116-9.
|
<32 weeks |
500-1500 |
33 |
10-5-5 |
Oral |
93.9 |
4545 Ghanem S, Mostafa M, Shafee M. Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. J Saudi Heart Ass. 2010;22:7-10.
|
29.3±1.2 |
1227±188 |
32 |
10-5-5 |
Oral |
84.3 |
1818 Cherif A, Khrouf N, Jabnoun S, Mokrani C, Amara MB, Guellouze N, et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics. 2008;122(6):e1256-61.
|
28.5±1.9 |
na |
52 |
10-5-5 |
Oral |
84.6 |
1919 Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr. 2011;158(4):549-54.
|
26.4±1.1 |
892±117 |
36 |
10-5-5 |
Oral |
83.3 |
7070 Erdeve O, Yurttutan S, Altug N, Ozdemir R, Gokmen T, Dilmen U, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2012;97(4):F279-83.
|